CIN85 Activators
The class of CIN85 activators presents a sophisticated array of chemical compounds strategically designed to intricately modulate cellular processes and signaling pathways, leading to the heightened functional activity of CIN85. Forskolin, an exemplary activator, exerts its influence by activating the cAMP/PKA pathway. As an adenylate cyclase activator, Forskolin elevates intracellular cAMP levels, directly impacting CIN85 activity. This activation is achieved through the specific regulation of PKA signaling, creating an optimal cellular milieu for the heightened functionality of CIN85 in various cellular processes.
Similarly, Retinoic Acid stands as another pivotal member of this activator class, operating through the modulation of the retinoic acid signaling pathway. Functioning as a retinoid, Retinoic Acid influences downstream targets, including CIN85. This direct activation occurs through the precise regulation of retinoic acid receptors, culminating in altered transcriptional regulation and heightened CIN85 functionality in cellular processes. These illustrative examples emphasize the intricacy of chemical modulation, providing a foundation for the development of targeted interventions intended to enhance CIN85 activity in specific cellular contexts. In summary, the diverse array of chemical compounds within the CIN85 activator class showcases a nuanced understanding of cellular processes, enabling the specific enhancement of CIN85 functionality through precise modulation of key signaling pathways. The unique mechanisms of action exhibited by these activators highlight the potential for targeted interventions, laying the groundwork for further investigations into the intricate regulatory networks governing CIN85 and its diverse roles in cellular physiology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin enhances CIN85 activity by activating the cAMP/PKA pathway. Acting as an adenylate cyclase activator, Forskolin elevates intracellular cAMP levels, directly influencing CIN85 activity. This direct activation occurs through specific regulation of PKA signaling, creating a conducive cellular environment for the heightened functionality of CIN85 in cellular processes. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic Acid provides another avenue for CIN85 activation by modulating the retinoic acid signaling pathway. As a retinoid, Retinoic Acid influences downstream targets, including CIN85. This direct activation occurs through the specific regulation of retinoic acid receptors, leading to altered transcriptional regulation and heightened CIN85 functionality in cellular processes. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM inhibits CIN85 by chelating intracellular calcium ions, disrupting calcium-dependent signaling pathways associated with CIN85 modulation. This inhibition occurs through the interference with calcium-dependent processes crucial for CIN85 regulation, highlighting the specific role of intracellular calcium signaling in the modulation of CIN85 activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 selectively inhibits CIN85 by targeting the TGF-β receptor, impeding TGF-β signaling crucial for CIN85 regulation. This direct inhibition disrupts the TGF-β-mediated signaling events involving CIN85, showcasing a targeted approach to inhibit CIN85 activity by interfering with specific receptor-mediated pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits CIN85 by targeting Rho-associated protein kinase (ROCK), disrupting the Rho/ROCK signaling pathway implicated in CIN85 modulation. This direct inhibition interferes with the ROCK-mediated events involving CIN85, providing a specific approach to attenuate CIN85 activity through modulation of the Rho/ROCK signaling axis. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA, a PKC activator, indirectly enhances CIN85 activity by activating the PKC signaling pathway. The activated PKC pathway, in turn, influences CIN85 functions, showcasing the indirect activation of CIN85 through modulation of the PKC pathway. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone, a PPARγ agonist, indirectly activates CIN85 by modulating the PPARγ pathway. The activation of PPARγ influences downstream events involving CIN85, providing an indirect mechanism for enhancing CIN85 functionality through the PPARγ pathway. | ||||||
Lysophosphatidic Acid | 325465-93-8 | sc-201053 sc-201053A | 5 mg 25 mg | $98.00 $341.00 | 50 | |
Lysophosphatidic Acid (LPA) activates CIN85 indirectly by influencing the LPA receptor-mediated signaling pathway. The activation of this pathway modulates CIN85 functions, highlighting the indirect activation of CIN85 through lipid signaling, providing an additional layer of complexity in the regulation of CIN85. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT inhibits CIN85 by interfering with the Notch signaling pathway. As a γ-secretase inhibitor, DAPT prevents the cleavage of Notch receptors, disrupting downstream events involving CIN85 and illustrating a targeted approach to inhibit CIN85 activity by modulating Notch signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits CIN85 by targeting PI3K, disrupting the PI3K/Akt signaling pathway implicated in CIN85 modulation. This direct inhibition interferes with the PI3K-mediated events involving CIN85, providing a specific approach to attenuate CIN85 activity through modulation of the PI3K/Akt signaling axis. | ||||||